Patents by Inventor Richard Houghten
Richard Houghten has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 5582997Abstract: Polypeptides, sets and libraries of sets of polypeptides that are related in sequence to the polypeptide of SEQ ID NO:1 are disclosed that have antimicrobial, hemolytic and hydrolytically catalytic activities, as are processes for making and using the same. A contemplated set is a mixture of equimolar amounts of a polypeptide of SEQ ID NO:2. Particularly preferred polypeptides include those of SEQ ID NOs:3-9.Type: GrantFiled: August 24, 1994Date of Patent: December 10, 1996Assignee: Torrey Pines Institute for Molecular StudiesInventors: Sylvie Blondelle, Richard A. Houghten, Enrique Perez-Paya
-
Patent number: 5578573Abstract: The present invention provides viral integrase inhibiting peptides having the general structure, ##STR1## where Xaa is an amino acid or an amino acid analog, the stereochemistry of the amino acids or amino acid analogs can be D-amino acids or L-amino acids and the amino and carboxy termini of the peptide can be modified. The invention also provides viral inhibiting peptides having essentially the amino acid sequence, ##STR2## The invention also provides a pharmaceutical composition comprising a viral integrase inhibiting peptide and methods of using a viral integrase inhibiting peptide in vitro or in vivo to reduce or inhibit viral integrase activity in a cell and the infectivity of a virus.Type: GrantFiled: January 20, 1995Date of Patent: November 26, 1996Assignee: Houghten Pharmaceuticals, Inc.Inventors: Richard A. Houghten, Patricia A. Weber, Ronald H. A. Plasterk, Ramon A. Puras Lutzke
-
Patent number: 5556762Abstract: Synthetic peptide combinatorial libraries (sets) having a single, predetermined amino acid residue at a single, predetermined oligopeptide chain position and mixtures of amino acid residues at the other chain positions are disclosed, as are their processes of synthesis and use in determining the amino acid residue sequence of an oligopeptide ligand that binds to an acceptor molecule.Type: GrantFiled: September 11, 1992Date of Patent: September 17, 1996Assignee: Houghten Pharmaceutical Inc.Inventors: Clemencia Pinilla, Jon R. Appel, Jr., Richard A. Houghten
-
Patent number: 5504190Abstract: A process for the synthesis of a complex mixture pool of solid support-coupled monomeric repeating unit compounds such as amino acid derivatives is disclosed in which the mixture pool contains an equimolar representation of reacted monomeric repeating unit compounds coupled. Also disclosed is a process for the stepwise synthesis of a complex mixture of coupled or free, unsupported oligomers such as oligopeptides. A set of self-solubilizing, unsupported mixed oligopeptides having one or more predetermined amino acid residues at one or more of the same, predetermined positions in the oligopeptide chain in which the set contains equimolar amounts of a plurality of different amino acid residues, preferably at least six different residues, at one or more of the same predetermined positions of the oligopeptide chain is also disclosed, as are methods of making and using the same.Type: GrantFiled: June 3, 1994Date of Patent: April 2, 1996Assignee: Torrey Pines Institute for Molecular StudiesInventors: Richard A. Houghten, Julio H. Cuervo, Clemencia Pinilla, Jon R. Appel, Jr., Silvie Blondelle
-
Patent number: 5480971Abstract: Linear C.sub.1 -C.sub.7 -alkyl peralkylated oligopeptide sets of molecules are specific peralkylated oligopeptides, disclosed, as are their methods of synthesis and use in acceptor binding assays. Each molecule or chain of a set contains the same number of two to about ten substituted C.sub.1 -C.sub.7 -alkyl peralkylated amino acid residues, and the member chains of a set are present in equimolar amounts. The chains of a set contain one or more predetermined peralkylated amino acid residues at one or more predetermined positions of the peralkylated oligopeptide chain. The set contains equimolar amounts of at least six different peralkylated amino acid residues at one or more of the same predetermined positions of the peralkylated oligopeptide chain. Libraries of such sets, processes for their use and solid support-linked peralkylated sets are also contemplated, as are specific permethylated oligopeptides such as those having 5-8 phenylalanine residues that have antimicrobial properties.Type: GrantFiled: June 9, 1994Date of Patent: January 2, 1996Assignee: Houghten Pharmaceuticals, Inc.Inventors: Richard A. Houghten, John M. Ostresh, Sylvie Blondelle
-
Patent number: 5478726Abstract: Recombinant 540 amino acid residue and 517 amino acid residue proteins encoded by the genome of Mycobacterium tuberculosis are disclosed as are vectors for propagating their DNA sequences and expressing the proteins. Also disclosed are methods for using those proteins. Peptides that correspond substantially to the sequences of those proteins and methods of their use are also disclosed, as are polymers containing peptide repeating units corresponding to the 540 residue protein and also polymers containing 517 protein pentapeptides as repeating units.Type: GrantFiled: December 18, 1992Date of Patent: December 26, 1995Assignee: The Scripps Research InstituteInventors: Thomas Shinnick, Richard Houghten
-
Patent number: 5441936Abstract: The present invention provides antiviral peptides having the general structure, Arg-Arg-Trp-Trp-Cys-Arg-X, where X is an amino acid or an amino acid analog, the stereochemistry of the amino acids or amino acid analogs can be (D)- or (L)-amino acids and the amino and carboxy termini of the peptide can be modified. The invention also provides a pharmaceutical composition comprising an antiviral peptide and methods of using an antiviral peptide in vitro or in vivo to reduce or inhibit a herpes simplex virus infection.Type: GrantFiled: December 7, 1993Date of Patent: August 15, 1995Assignee: Houghten Pharmaceuticals, Inc.Inventors: Richard A. Houghten, Patricia A. Weber
-
Patent number: 5440016Abstract: Peptides having Anti-microbial activity and having the formula (KFmoc)ZZZ-NH.sub.2, wherein Z is an amino acid are disclosed. Also disclosed are peptides having anti-trypsin activity and having the formula Ac-rypwz-NH.sub.2, wherein z is a D-amino acid. Also disclosed are compositions containing these peptides and methods of using them.Type: GrantFiled: June 18, 1993Date of Patent: August 8, 1995Assignee: Torrey Pines Institute for Molecular StudiesInventors: Sylvie E. Blondelle, Richard A. Houghten
-
Patent number: 5420109Abstract: The present invention provides novel cytokine restraining agents, which limit or control the biological activity of cytokines. The invention also provides pharmaceutical compositions comprising a cytokine restraining peptide and methods of administering the pharmaceutical composition to a subject. The invention further provides methods for using the novel peptides to restrain cytokine activity in a subject.Type: GrantFiled: November 12, 1993Date of Patent: May 30, 1995Assignee: Houghten Pharmaceuticals, Inc.Inventors: Mark J. Suto, Beverly E. Girten, Richard A. Houghten, Costas C. Loullis, Ronald R. Tuttle
-
Patent number: 5367053Abstract: This invention provides novel peptides having the ability to inhibit binding of the mu specific ligand .sup.3 H-[D-Ala.sup.2,MePhe.sup.4,Gly-ol.sup.5 ]enkephalin ("DAGO") to the opioid receptors in crude rat brain homogenate.Type: GrantFiled: May 19, 1993Date of Patent: November 22, 1994Assignee: Houghten Pharmaceuticals, Inc.Inventors: Colette T. Dooley, Richard A. Houghten
-
Patent number: 5294605Abstract: A process for inhibiting growth of a target cell comprising administering to a host or to a target cell or virus a biologically active peptide which includes one of the following basic structures; R.sub.1 -R.sub.1 -R.sub.2 -R.sub.1 -R.sub.1 -R.sub.2 -R.sub.2 -R.sub.1 -R.sub.1 -R.sub.2 -R.sub.2 -R.sub.1 -R.sub.2 -R.sub.2 ; R.sub.2 -R.sub.1 -R.sub.1 -R.sub.2 -R.sub.2 -R.sub.1 -R.sub.2 -R.sub.2 -R.sub.1 -R.sub.1 -R.sub.2 -R.sub.2 -R.sub.1 -R.sub.1 ; or R.sub.1 -R.sub.2 -R.sub.1 -R.sub.1 -R.sub.2 -R.sub.2 -R.sub.1 -R.sub.1 -R.sub.2 -R.sub.2 -R.sub.1 -R.sub.2 -R.sub.2 -R.sub.1 -R.sub.1 -R.sub.2 -R.sub.2 -R.sub.1, wherein R.sub.1 is a hydrophobic amino acid, and R.sub.2 is a basic hydrophilic or neutral hydrophilic amino acid. A preferred peptide is of the structural formula:(SEQ ID NO:3).Substitution and deletion analogues of this peptide can be prepared that have increased biological activity. Such peptides can be employed as pharmaceuticals.Type: GrantFiled: July 8, 1991Date of Patent: March 15, 1994Assignee: The Scripps Research InstituteInventors: Richard A. Houghten, Sylvie Blondelle
-
Patent number: 5238919Abstract: This invention provides a peptide fragment of human von Willebrand Factor (vWF) and sub-fragment thereof isolated as enzymtic digestion products from naturally occurring human vWF, or isolated from synthetic peptide mixtures or isolated from lysates of organisms capable of producing recombinant human vWF. The fragments and sub-fragments are useful in the prevention and treatment of cardiovascular disorders by virtue of their ability to inhibit the binding of vWF to platelets, heparin and/or collagen.Type: GrantFiled: May 7, 1990Date of Patent: August 24, 1993Assignee: Scipps Clinic and Research FoundationInventors: Theodore S. Zimmerman, Yoshihiro Fujimura, Richard A. Houghten, Zaverio M. Ruggeri
-
Patent number: 5235038Abstract: A compound comprising an analogue of the melittin peptide having the following structural formula: ##STR1## wherein at least one and no more than four amino acid residues are omitted from the peptide, or at least one of amino acid residues 1-6, 8-18, or 20-26 in the peptide is substituted with a hydrophobic residue, provided that no more than two of amino acid residues 21-26 is substituted with a hydrophobic residue. Such deletion and substitution analogues are useful as antibiotics, antimicrobial agents, antifungal agents, anti-tumor agents, antiviral agents, or agents which stimulate wound healing.Type: GrantFiled: January 22, 1991Date of Patent: August 10, 1993Assignee: Torry Pines Institute for Molecular StudiesInventors: Sylvie E. Blondelle, Richard A. Houghten
-
Patent number: 5122448Abstract: Antigens, immunogens, inocula, antibodies, and particularly diagnostic methods and systems relating to Epstein-Barr virus nuclear antigen (EBNA) are disclosed. The diagnostic methods and systems utilize a synthetic, random copolymer polypeptide containing about 8 to about 40 amino acid residues that includes the overlapping five and six amino acid residue sequences--Gly--R.sup.1 --Gly--R.sup.2 --Gly-- (i)wherein R.sup.1 and R.sup.2 are amino acid residues selected from Ala, Asn, Arg, Gly, Leu, Pro, Ser, and Thr with the provision that R.sup.1 and R.sup.2 are not both Gly; and--Gly--Ala--Gly--Gly--Ala--Gly--. (ii)The polypeptide contains at least 50 mole percent Gly residues. The diagnostic method and system are particularly useful for assaying for the stage of mononucleois disease, and the presence of nasopharynegeal carcinoma.Type: GrantFiled: January 11, 1990Date of Patent: June 16, 1992Assignee: Scripps Clinic and Research FoundationInventors: John H. Vaughan, Dennis A. Carson, Gary Rhodes, Richard Houghten
-
Patent number: 5116725Abstract: Antigens, immunogens, inocula, antibodies, and particularly diagnostic methods and systems relating to Epstein-Barr virus nuclear antigen (EBNA) are disclosed. The diagnostic methods and systems utilize a synthetic, random copolymer polypeptide containing about 8 to about 40 amino acid residues that includes the overlapping five and six amino acid residue sequences(i) --Gly--R.sup.1 --Gly--R.sup.2 --Gly--wherein R.sup.1 and R.sup.2 are amino acid residues selected from Ala, Asn, Arg, Gly, Leu, Pro, Ser, and Thr with the provision that R.sup.1 and R.sup.2 are not both Gly; and(ii) --Gly--Ala--Gly--Gly--Ala--Gly--.The polypeptide contains at least 50 mole percent Gly residues. The diagnostic method and system are particularly useful for assaying for the stage of mononucleois disease, and the presence of nasopharynegeal carcinoma.Type: GrantFiled: November 4, 1987Date of Patent: May 26, 1992Assignee: Scripps Clinic and Research FoundationInventors: John H. Vaughan, Dennis A. Carson, Gary Rhodes, Richard Houghten, Richard S. Smith, John E. Geltosky
-
Patent number: 4976958Abstract: Recombinant 540 amino acid residue and 517 amino acid residue proteins encoded by the genome of Mycobacterium tuberculosis are disclosed as are vectors for propagating their DNA sequences and expressing the proteins. Also disclosed are methods for using those proteins. Peptides that correspond substantially to the sequences of those proteins and methods of their use are also disclosed, as are polymers containing peptide repeating units corresponding to the 540 residue protein and also polymers containing 517 protein pentapeptides as repeating units.Type: GrantFiled: February 24, 1988Date of Patent: December 11, 1990Assignee: Scripps Clinic and Research FoundationInventors: Thomas Shinnick, Richard Houghten
-
Patent number: 4962277Abstract: A compound comprising a deletion analogue of an amide or carboxy-terminating Magainin I of the following structural formula using the single letter amino acid code: ##STR1## and wherein at least one of amino acid residues 15 through 23 is omitted; or a deletion analogue of an amide or carboxy-terminated Magainin II of the following structural formula using the single letter amino acid code: ##STR2## and wherein at least one of amino acid residues 15 through 23 is omitted. These compounds can be effectively used as pharmaceutical compositions.Type: GrantFiled: December 9, 1988Date of Patent: October 9, 1990Assignee: Scripps Clinic and Research FoundationInventors: Julio H. Cuervo, Richard A. Houghten
-
Patent number: 4952395Abstract: Recombinant 540 amino acid residue and 517 amino acid residue proteins encoded by the genome of Mycobacterium tuberculosis are disclosed as are vectors for propagating their DNA sequences and expressing the proteins. Also disclosed are methods for using those proteins. Peptides that correspond substantially to the sequences of those proteins and methods of their use are also disclosed, as are polymers containing 517 protein pentapeptides as repeating units.Type: GrantFiled: February 26, 1987Date of Patent: August 28, 1990Assignee: Scripps Clinic and Research FoundationInventors: Thomas Shinnick, Richard Houghten
-
Patent number: 4889800Abstract: Antigens, immunogens, inocula, antibodies, receptors, diagnostic methods and systems relating to tuberculosis mycobacteria are disclosed. Each of the compounds, compositions, methods or systems contains about 40 residues, or an antibody containing site that immunoreacts with such a polypeptide. The polypeptide includes the thirteen or fourteen amino acid reside sequence (AlaLysValAsnIleLysProLeuGluAspLysIleCys) or (CysAlaLysValAsnIleLysproLeuGluAspLysIleCys). When linked to a carrier and introduced in an effective amount into a mammalian host, the polypeptide is capable of inducing production of antibodies that immunoreact with an antigen to a tuberculous mycobacterium.Type: GrantFiled: August 21, 1987Date of Patent: December 26, 1989Assignee: Scripps Clinic and Research FoundationInventors: Thomas M. Shinnick, Percy Minden, Richard A. Houghten
-
Patent number: 4886663Abstract: A synthetic polypeptide having at least about 10% of the immunological activity of biologic heat-stable enterotoxin of E. coli. The synthetic polypeptide includes at least 14 amino acids in the sequence, from amino-terminus to carboxy-terminus, represented by the formula: CysCysGluLeuCysCysTyr-(Asn)ProAlaCysAla(Thr)GlyCysAsn(Tyr) wherein the amino acid in parentheses may replace the immediately preceding amino acid residue, and at least one intramolecular disulfide bond formed between the Cys residues. The Cys residues that are not part of the intramolecular disulfide bond can be replaced by other amino acid residues or be bonded to substituent moieties. The polypeptides can be a monomeric or multimeric material containing an intramolecular, intrapolypeptide and/or an intramolecular, interpolypeptide cystine disulfide bond.Type: GrantFiled: December 12, 1983Date of Patent: December 12, 1989Assignee: Scripps Clinic and Research FoundationInventor: Richard A. Houghten